FNY Investment Advisers LLC acquired a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 30,818 shares of the company's stock, valued at approximately $516,000.
Other institutional investors have also added to or reduced their stakes in the company. Bourgeon Capital Management LLC increased its holdings in Teva Pharmaceutical Industries by 100.7% during the second quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company's stock worth $12,134,000 after buying an additional 363,252 shares during the last quarter. Amundi increased its holdings in Teva Pharmaceutical Industries by 18.5% during the first quarter. Amundi now owns 678,758 shares of the company's stock worth $10,080,000 after buying an additional 105,846 shares during the last quarter. IFM Investors Pty Ltd increased its holdings in Teva Pharmaceutical Industries by 9.4% during the second quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company's stock worth $3,797,000 after buying an additional 19,447 shares during the last quarter. Jump Financial LLC increased its holdings in Teva Pharmaceutical Industries by 172.1% during the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company's stock worth $20,373,000 after buying an additional 838,423 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in Teva Pharmaceutical Industries by 5.7% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company's stock worth $38,487,000 after buying an additional 134,705 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
TEVA has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Saturday, October 11th. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an "overweight" rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of "Buy" and an average target price of $25.57.
View Our Latest Stock Report on TEVA
Teva Pharmaceutical Industries Trading Down 2.1%
Shares of Teva Pharmaceutical Industries stock opened at $19.01 on Wednesday. The firm has a 50-day moving average of $19.00 and a 200-day moving average of $17.18. The stock has a market cap of $21.80 billion, a PE ratio of -118.78, a PEG ratio of 1.07 and a beta of 0.71. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. Teva Pharmaceutical Industries's quarterly revenue was up .3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.
Insider Transactions at Teva Pharmaceutical Industries
In other news, insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Placid Jover sold 6,053 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares of the company's stock, valued at approximately $102,693.84. The trade was a 47.19% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.55% of the company's stock.
About Teva Pharmaceutical Industries
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
